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Older adults experience hallucinations in a variety of so-
cial, physical, and mental health contexts. Not everyone 
is open about these experiences, as hallucinations are sur-
rounded with stigma. Hence, hallucinatory experiences 
in older individuals are often under-recognized. They are 
also commonly misunderstood by service providers, sug-
gesting that there is significant scope for improvement in 
the training and practice of professionals working with 
this age group. The aim of the present article is to increase 
knowledge about hallucinations in older adults and provide 
a practical resource for the health and aged-care work-
force. Specifically, we provide a concise narrative review 
and critique of (1) workforce competency and training is-
sues, (2) assessment tools, and (3) current treatments and 
management guidelines. We conclude with a brief summary 
including suggestions for service and training providers and 
future research.
Key words:  hallucinations/assessment/treatment/older 
adults/training/aged-care
General Introduction 
By 2050, it is estimated that 16% of people will be aged 
above 65 years, compared with 9% in 2019.1 Population 
aging is driving increased attention to the physical and 
mental health needs of older adults. Here, our focus is 
on hallucinations—given the wide range of health and 
aged-care service providers who encounter people with 
these experiences in their workplace. Hallucinations 
can be defined as “a perception-like experience with 
the clarity and impact of a true perception but without 
the external stimulation of the relevant sensory organ” 2 
(cf. 3–5), though this belies the difficulty in discerning the 
boundaries between normal and abnormal perception.6 
Hallucinations need to be distinguished from illusions, 
which are perceptual experiences in which an external 
stimulus is misperceived or misinterpreted.2 In practice, 
hallucinations vary in content (eg, perception of people, 
animals, or objects), character (eg, frequency, emotional 
valence, location), duration (from seconds to chronically 
present), complexity (eg, perception of simple stimuli vs 
organized scenes or objects), and quality (eg, perceived 
reality, intrusiveness) and occur in all sensory modalities. 
The terms used to refer to hallucinations are equally di-
verse (see table 1).
Hallucinations occur in people with sensory, neurolog-
ical, medical, neurodegenerative, and psychological dis-
orders7 as well as in those with no mental disorder at all.8–10 
In healthy (nonclinical) samples, hallucination prevalence 
(across modalities) is lower in older than younger adults.8,9 
In contrast, hallucinations are common in many clinical 
disorders associated with older age, with specific prevalence 
rates varying by condition, stage of illness, and symptom 
type. For example, visual hallucinations are common in de-
mentia, Parkinson’s disease, and in eye or visual pathway 
disease,11 while auditory hallucinations are prevalent with 
hearing loss.12 Similarly, multimodal visual, tactile, and 
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auditory hallucinations tend to be more prominent in 
late- (between 40 and 60 years age) or very-late onset (60+ 
years) compared with early-onset schizophrenia.13 Across 
conditions, both similarities and differences have been re-
ported,14,15 suggesting that the same assessments and treat-
ments may not be appropriate for all presentations of 
hallucinations in older adults, which may be linked to the 
diversity of risk factors involved.16–19
Whilst our understanding, assessment, and treat-
ment of hallucinations in older adults have improved 
in the last decade, greater priority needs to be given to 
communicating these advances to clinicians so that clinical 
care can be grounded in the best available evidence. The 
International Consortium of Hallucinations Research 
Working Group on Hallucinations in Older Adults was 
set up to respond to this challenge. Accordingly, the pur-
pose of this review is to highlight the key issues for the 
workforce caring for older adults with hallucinations; 
critically review current assessment tools, management 
guidelines, and treatment approaches for this population; 
and offer recommendations and resources to support 
best practice.
Table 1. Key Terms and Definitions of Hallucinations 
Type of Hallucina-
tion Related Terms Definition
Bereavement hallu-
cinations
➢ Grief  hallucinations  
➢ Sensed presence  
➢ Experience of continued presence  
➢ Guardian angel experience
The experience of seeing, hearing, feeling, tasting, smelling, and/
or sensing the presence of the deceased.
Charles Bonnet syn-
drome
➢ “Phantom vision” syndrome Typically involves the experience of complex (ie, formed) visual 
hallucinations, in the context of visual loss, with insight that the 




 The involuntary perception of an object or scene in the absence of 
a corresponding object/scene in the environment (ie, a formed  
perception whereby individual features have been linked or 
grouped into organized/connected wholes).
Hallucinations ➢ Private perceptions  
➢  Hearing voices (in the case of auditory  
hallucinations)  
➢  Seeing visions (in the case of visual  
hallucinations)  
➢ Unusual sensory experiences  
➢ Anomalous perceptions
“A sensory experience which occurs in the absence of corre-
sponding external stimulation of the relevant sensory organ; has a 
sufficient sense of reality to resemble a veridical perception, over 
which the subject does not feel s/he has direct voluntary control 
and which occurs in the awake state.” 3  
“an erroneous percept in the absence of identifiable stimuli.” 4  
“[Perceiving] something involuntarily which, by all other  




➢ Sleep-related hallucinations Vivid, dreamlike experiences that occur on the borders of sleep 
These anomalous perceptions can occur when falling asleep  
(hypnogogic) or waking up (hypnopompic).
Multimodal  
hallucinations
➢ Compound hallucinations  
➢ Polymodal hallucinations  
➢ Polysensual hallucinations  
➢ Intersensorial hallucinations
Hallucinations that occur in more than one modality  
simultaneously, typically emanating from a single source. NB. 




➢ Musical hallucinosis  
➢ Musical ear syndrome  
➢ Auditory Charles Bonnet syndrome  
➢ Oliver Sack’s syndrome
The subjective experience of hearing music, or aspects of music, 
when none is being played. The perception of music can occur 
with or without voice and lyrics.
Olfactory  
hallucinations
➢ Phantosmia  
➢ Phantom smells
The detection of smells, when the corresponding odor is not 
present in the environment.
Passage  
hallucinations
➢  Sometimes referred to as  
“minor hallucinations”




➢ Feeling of presence  
➢ Sensed presence
The vivid sensation of the presence of another person or agent, 
usually close by, or just behind, the perceiver.
Simple  
hallucinations
 The perception of unformed stimuli (eg, colored lines,  
high-pitched tones), when there are no such stimuli in the  
environment (ie, perceptions involving specific stimulus features 
rather than whole objects).
Tactile  
hallucinations
➢ Hallucinations of touch The perception of a tactile stimulus that is not explained by the 
actions of another person or external object
Tinnitus ➢ Often called “ringing in the ears” The perception of noises in one or both ears or inside the head, 
when no external sound source is present. Sounds often involve 
ringing, hissing, whistling, or buzzing but can be more complex 
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Workforce Competencies and Training Issues
As familiar and trusted advisors, primary care phys-
icians can play a critical role in the early phases of as-
sessment and treatment of hallucinations in older adults 
by: debunking myths and stereotypes (eg, that everyone 
who hallucinates has a psychotic disorder), providing rel-
evant facts about hallucinations (eg, that distress asso-
ciated with hallucinations can be treated), liaising with 
the client’s primary and specialist care network, and ar-
ranging referral (eg, when trauma or bereavement are 
central factors in distressing hallucinations). However, 
hallucinations are also reported in general hospital ad-
missions,20,21 emergency departments,22 routine health-
care appointments, and by residents in long-term care.23 
Consequently, staff  in all these settings need up-to-date 
knowledge and skills to offer optimal care and support 
that fits the client’s needs.
Client-Centered Factors
Both complex and simple hallucinations can be a cause 
of considerable disruption to daily life (eg, aggressive be-
havior, falls, social withdrawal) and distress. For example, 
tinnitus—the experience of a persistent sound in the ab-
sence of an external source—can provoke anxiety, lone-
liness, and anger.24 Similarly, hallucinations associated 
with postoperative delirium can be highly distressing and 
may contribute to the development of post-traumatic 
stress disorder.25 These negative responses can be exacer-
bated by unhelpful interactions with the treating team 
(eg, when clinicians convey a lack of hope). Similarly, 
people with dementia and Parkinson’s disease may show 
an initial phase of uncertainty and distress when hallucin-
ations first begin, which abates when patients learn that 
the experiences are not real.26 It is important to recognize, 
however, that hallucinations are relatively common in 
“healthy” older adults (ie, in the absence of psychotic dis-
order or dementia8,16) and are not necessarily distressing. 
For example, in Charles Bonnet syndrome, a variety of 
positive emotional responses (amusement, curiosity) have 
been reported.27 That said, the role of emotions in hal-
lucinations is often complex. For instance, older people 
who are lonely may be fearful that the treatment team 
will “take them away from them”—depriving them of 
the sense of social connection that hallucinations some-
times provide. Similarly, bereavement hallucinations, 
which are a common reaction after a loss, are not only 
often regarded as positive,17,28,29 but are also associated 
with higher levels of depression, anxiety, and clinically 
impairing grief.17,30
Culture also has a significant influence on the meaning, 
content, and expression of hallucinations—as well as 
with beliefs about treatment.31,32 Voice-hearing experi-
ences tend to be viewed as more negative and threatening 
in high-income countries and more benign in low- or 
middle-income countries.33 Consequently, official guide-
lines and training programs now include cultural diversity 
as part of competency-based curricula,34 and developing 
culturally safe practice is considered particularly impor-
tant when working with indigenous people, First Nations, 
Native peoples, or Aboriginal and Torres Strait Islander 
communities in Australia.35
Negative stereotypes about hallucinations can hinder 
the disclosure of these experiences, leading to delays in 
accessing help.26,36 For instance, hallucinations are often 
considered synonymous with psychotic disorder, which is 
frequently stereotyped in terms of dangerousness and in-
competence. As a result, older adults with hallucinations 
are often concerned that they are becoming mentally ill 
or developing dementia and worry about how treating 
clinicians will respond.37 Concerns about social disap-
proval can also lead to the same perceptual experience 
being described quite differently in different contexts.38 
As a general point, adopting the terminology that older 
adults use when describing their experiences can often 
help the clinician to gain a better insight into their client’s 
understanding of hallucinations.
Practitioner-Centered Factors
Low levels of knowledge about aging and hallucinations 
remain an ongoing issue amongst many professionals.39 
For example, some ophthalmologists and general prac-
titioners remain unfamiliar with visual hallucinations 
arising from eye disease (ie, Charles Bonnet syndrome)—
and consequently rarely discuss the possibility of hal-
lucinatory experiences in patients with visual loss.27,37,40 
Similarly, auditory hallucinations are common in people 
with hearing impairment, which suggests that clinicians 
should enquire about hallucinations in hearing-impaired 
patients and assess hearing ability in older people with 
recent-onset auditory hallucinations.12
Biased thinking about hallucinations can also occur, 
despite the good intentions of staff  to help their clients/
patients. For example, fear that people with hallucin-
ations might be dangerous may lead to less willingness 
to discuss voice-hearing experiences with patients.41 In 
general, negative stereotypes have been shown to be as-
sociated with less focus on the patient (than the disease), 
lower endorsement of recovery as an outcome of care, 
and fewer referrals for specialist treatment42 (see also ref-
erence 43). Consequently, a growing number of programs 
are being trialed that promote stigma reduction and sup-
portive, nonjudgmental attitudes toward hallucinations 
in healthcare professionals and students44 (see table 2).
Finally, it is important for clinicians to think about 
the needs of the caregivers as well as the patient. For ex-
ample, informal caregivers can find managing visual hal-
lucinations in Parkinson’s challenging, which can have a 
negative impact on their quality of life.26 Consequently, 
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the person experiencing hallucinations to providing 
psychoeducation (eg, about causes of hallucinations) and 
support (eg, coping methods) for the person who cares 
for them.
Assessment Tools
For the purposes of this review, clinicians and researchers 
with particular expertise in hallucinations in older popu-
lations were asked to provide a list of key elements that 
underpin high-quality assessment tools as well as features 
specifically relevant to tools for assessing hallucinations 
in older adults (step 1). Thereafter, these same experts 
were asked to provide a list of existing assessment tools 
for hallucinations that may be used with older adults and 
describe their strengths and limitations (step 2). Finally, 
these assessment tools were summarized and compared 
with the elements from step 1.
Criteria for Assessment Tools
A list of the key elements that underpin high-quality as-
sessment tools is presented in table 345,46 whereby general 
issues are presented first, followed by psychometric, struc-
tural, and practical issues that are specific to the assess-
ment of hallucinations and to the context of assessing 
older adults in particular.
Summary of Existing Assessment Tools for 
Hallucinations
Table 4 presents a selection of commonly used assessment 
tools for hallucinations, along with a brief  summary of 
their psychometric properties, and their strengths and 
limitations. Of note, the majority of these measures were 
not developed specifically for older adults—so that their 
design was not necessarily based on the needs of older 
adults or any specific characteristics of hallucinations in 
older age groups.
In table 4, it can be seen that, compared with self-re-
port measures, there are relatively few clinician-
administered tools regularly used with older adults. One 
of these (Assessment of Phantosmia) is for a very spe-
cific type of hallucination (ie, only for olfactory hallucin-
ations), although it has been used in older populations67 
(cf. 68). Another tool, the Auditory Hallucinations Rating 
Scale62,63 is quite brief  and assesses just auditory hallu-
cinations, but is not widely used (for transcranial mag-
netic stimulation studies only). The North East Visual 
Hallucinations Inventory64–66 has good psychometric 
properties and was developed with older populations in 
mind but assesses only visual hallucinations. The final 
two interview tools—the Psychotic Symptom Rating 
Scales (PSYRATS)60 and the Questionnaire for Psychotic 
Experiences (QPE)69—are quite similar, in that both are 
detailed in the number of dimensions they assess, al-
though the QPE offers a more complete assessment of 
hallucinations modalities and delusions, whereas the 
PSYRATS assesses delusions but only auditory hallu-
cinations.61 Important to note is that the PSYRATS was 
developed for the assessment of patients with psychotic 
disorder, so it is arguably less suitable for older clinical 
groups where, eg, visual (and other) hallucinations dom-
inate. However, the PSYRATS does show sensitivity 
to change and is, therefore, widely used in evaluating 
the treatment of hallucinations (cf. 70–73). Although the 
PSYRATS has been in use for two decades, to the best 
of our knowledge, it has not been systematically inves-
tigated in older populations. Finally, it is still unknown 
if  hallucination measures are invariant across samples, 
making comparisons of scores between different samples 
(eg, older adults and people with psychosis) invalid.
In terms of self-report measures, many of these assess 
hallucinations in a number of different modalities (eg, 
Cardiff  Anomalous Perceptions Scale, CAPS53–55; Multi-
Modality Unusual Sensory Experiences Questionnaire, 
MUSEQ59; Launay-Slade Hallucinations Scale, LSHS47; 
Extended LSHS48–50), and others are less comprehensive 
(eg, Community Assessment of Psychic Experiences, 
CAPE,51,52 and Current CAPE-15).58 Some measures 
were designed to assess hallucinatory experiences in 
older populations with a particular disorder—such as 
Parkinson’s disease, eg, Psychosis and Hallucination 
Questionnaire56,57—whilst others were not specifically 
created for assessing hallucinations in a particular dis-
order (CAPS and E-LSHS) but have recently been used in 
the clinical studies of older populations, eg, the E-LSHS 
has been used in people with Alzheimer’s and older 
nonclinical populations.74–76 However, as with clinician-
administered tools, very little research has directly com-
pared the use of these self-report measures across age 
groups, ie, younger vs older adults (but see8,77) and/or di-
agnostic groups (ie, clinical vs nonclinical), and it, there-
fore, remains largely unknown whether these tools are 
sample invariant. This is important to consider, because 
if  older adults are shown to be using existing tools dif-
ferently to younger adults, then changes may need to be 
made to these tools to accommodate for this; in turn, this 
will help to ensure that these experiences can be assessed, 
and validly compared, across different groups.
Overall, clinician-administered interviews are often 
already in a suitable and convenient format for older 
adults—difficulty reading due to visual loss/impairment, 
items can be repeated for those with hearing loss—though 
clinicians sometimes lack confidence in talking about hal-
lucinations, so formal training is required to learn how to 
approach this topic and to administer items in a standard-
ized way. For example, the QPE,69 which was developed 
with input from patient associations in several countries, 
provides 50 fully structured questions about hallucin-
ations and is scripted to be low in stigma. However, inter-
views can be time-consuming, which may be a problem 
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conclude, there is a clear need for an increased interest in 
hallucinations in older adults, both in terms of research 
in general and in terms of clinical practice (eg, the devel-
opment and validation of optimal hallucination assess-
ment tools for older adults and the existence of formal 
clinical training related to hallucinations in older adults). 
We encourage those working in a clinical setting to use the 
information presented here to choose the optimal halluci-
nation assessment tools for their working context. These 
assessment issues are as important in a clinical setting as 
they are in research. Also, we recommend that clinicians 
strive to further adapt, refine, and validate these tools to 
reduce the gap in evidence-based assessment tools avail-
able for older adults.
Management and Treatment Approaches
Current guidelines and treatment recommendations are 
largely based on expert consensus. The focus is typically 
on the overall management of a specific clinical condi-
tion, with hallucinations one of the symptoms covered, 
eg, NICE Guidelines for Parkinson’s disease.78 To date, 
Table 2. Recommendations for Training and Practice
Training and Practice Points Examples
➢  Training should sensitize future professionals to the complex  
nature of hallucinations in psychotic and nonpsychotic disorders  
and raise awareness that hallucinations can, and do, occur in the  
absence of a diagnosis of mental illness or a need for care.
Training should aim to:  
1)  Provide knowledge about the multifactorial nature of  
hallucinations—individual features of the experience are complex 
(they can vary in content, emotional valence, frequency, duration, 
reality, location, distress, control, etc).  
2)  Increase understanding that hallucinations have multiple causal 
risk factors. Though not an exhaustive list, this includes: physical 
(eg, sensory loss/impairment, intoxication, drug abuse/withdrawal, 
inflammation), psychological (eg, trauma, bereavement, impaired 
cognition, disrupted sleep), and social (eg, loneliness and social 
isolation, discrimination) factors.  
3)  Challenge myths and stereotypes, eg, that hallucinations occur 
only in people with psychotic disorders, indicate a propensity to 
violence, or are untreatable. Know the facts: hallucinations occur 
not only in people with different diagnoses but also in the healthy 
population and often respond to treatment.  
4)  Challenge beliefs about the need for care—hallucinations are 
sometimes viewed as helpful and positive, are not always  
associated with distress or disruption to daily life, and may not 
need an intervention.
➢  Affirming, non-judgmental attitudes and behavior may  
encourage self-reporting and alleviate distress arising from  
hallucinations in older adults
The following approaches may be helpful:  
1)  Avoid trivializing or invalidating the patients’ experience and how 
it makes them feel.  
2)  Ask the patient what their hallucinatory experience is like: 
everyone’s experience is different. What (if  anything) bothers them 
most? Communicate your understanding of what they have said 
back to them, to check you have understood them correctly.  
3)  Be patient, listen carefully, imagine being the person experiencing 
hallucinations—put yourself  in their shoes.  
4)  Ask the patient if  there are things that do or do not help them 
cope with their hallucinations.
➢  When enquiring about the experience of hallucinations 
with older adults and their families/carers use non-
stigmatizing language and provide accurate information 
about the help that is available.
Non-stigmatizing ways of asking about hallucinations include:  
“People sometimes hear another person speak, while there is no one 
there. Also, music or other sounds can be heard, while it is unclear 
where this comes from. In the past 7 days, have you ever heard such 
voices, music, or other sounds?”  
“Over the past 7 days, have you seen things or images when there was 
no clear explanation for them? Or when no one else could see them? 
For example, people, animals, shadows, specific patterns, or objects?”  
“People sometimes smell the scent of smoke, when there is no fire. 
Another example is someone who smells flowers, while there are no 
flowers around. Have you ever had this experience in the past 7 days?” 
“People sometimes say they experience hearing and seeing things that 
others cannot see or hear both at the same time. Or they feel some-
thing/someone touching them they can also see, while others do not. 
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few guidelines have focused on hallucinations specif-
ically (eg, 79) and the forthcoming SHAPED (Study of 
Hallucinations in Parkinson’s disease, Eye disease, and 
Dementia) consensus guidelines will be the first to focus 
on visual hallucinations in older adults.
All guidelines for hallucinations take the view that 
different treatments for hallucinations are required 
at different disease or hallucination stages and that 
experiencing hallucinations may not, in itself, require a 
specific treatment beyond general measures (eg, educa-
tion, reassurance, physical, and medication review). For 
example, the SHAPED guidelines suggest including a re-
view of cognitive and ophthalmological health, given that 
these may be masked by other conditions: ie, cognitive 
impairment may be missed in a patient with eye disease 
with their decline in functional ability attributed to visual 
Table 3. Quality Criteria for Assessment Tools
General: Applies to All Measurement Tools
Possesses good psychometric propertiesa Content validity, internal consistency, construct validity, criterion  
validity, test-retest reliability, responsiveness (ie, ability to detect clini-
cally important changes over time), floor and ceiling effects,  
cross-cultural validity, and interpretability (ie, the degree to which one 
can assign qualitative meaning to quantitative scores).
Clear and relevant instructions State time period(s), ask participants to answer all the items, tell  
participants to exclude certain experiences or contexts (eg, “please 
do not include experiences where alcohol, cannabis, ecstasy, or other 
similar substances has been taken”), explain the response scale (eg, 
for 5-point response scales, inform participants to use the entire scale 
and not just the extreme points), and include “unsure/do not know” 
response possibility.
Items should be clear and understandable eg, use a clear typeface and legible font size. 
Specific: Applies to Measurement Tools for Hallucinations  
and in Older Populations
Evidence that it is appropriate and feasible for use with older 
adults
eg, adequate tool when used specifically with older adults, including 
those with sensory and cognitive limitations, or physical ill-health.
Psychometric properties are robust when used with older  
populations
eg, factor invariance between older and younger adults reported, items 
cover all possible types/modalities of hallucinations (content validity), 
test-retest reliability reported (to help clinicians calculating reliable 
change indices), and evidence of sensitivity to change the following 
treatment.
Captures hallucination-related experiences eg, illusions, misperceptions, intrusive thoughts, flashbacks, 
daydreaming, etc. and able to distinguish these from hallucinations.
Assessment beyond presence/absence of hallucinations eg, frequency, variation, location, associated other factors (eg, lighting, 
presence of other people, etc.), consistent or variable (is there temporal 
consistency?), and impact of the experiences on the person (practical, 
emotional, etc.)
Inclusion of additional dimensions associated with the experience eg, whether or not the experience is associated with a certain degree of 
distress, conviction, preoccupation, etc.
Inclusion of (a) precise timeframe(s) Specific timeframes (eg, “Have you had this experience in the past 
year?”) and/or lifetime timeframes (eg, “Have you ever had this  
experience?”). Further, time periods assessed must be able to capture 
the new or recent onset of hallucinations vs hallucinations experienced 
throughout life.
Question addressing whether or not the individual has talked 
about the experience(s) with others
eg, “Have you discussed these experiences with your partner, carer, or 
doctor?”
Different versions of the measure available Versions for: self, informant, clinician.
Question about the interpretability of the items Whether or not the items were clear to the participant (and if  not, 
which one(s) were unclear/difficult).
Inclusion of a brief screener To identify people for whom a more detailed assessment may be  
warranted.
Introductory text states that the experiences have been shown to 
be quite common
However, this needs to be done carefully, so that these experiences are 
not further stigmatized.
Assessment beyond hallucinations eg, hearing, vision, health, cognition, medication (and any other  
variables that may be considered causally related to the hallucinatory 
experience in question), to help distinguish between age-related  
sensory change and perceptual anomalies.
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Table 4. Selected Examples of Assessment Tools for Hallucinations
Measure Brief  Description






Designed to assess hallucination  
predisposition in the general community.  
Original  
version has 12 items (Launay and Slade47); 
an extended version has 16 items.48  
Items rated on a 5-point Likert scale:  
“0 = certainly does not apply to me,”  
“1 = possibly does not apply to me,”  
“2 = unsure,” “3 = possibly applies  
to me,” and  
“4 = certainly applies to me.”
The E-LSHS has good validity 
and internal reliability (Cronbach’s 
α = .87).49,50  
Factor analyses of the E-LSHS indicate 
a 4-factor solution measuring; (a)  
auditory and visual HLEs, (b) 
multisensory HLEs, (c) intrusive 
thoughts, and (d) vivid daydreams.  
Psychometric data in older adults are 
currently being examined. For the 3 
LSHS auditory hallucinations items, 
Cronbach’s α = .869 in adults 60+ yrs 
(data derived from reference 8).
E-LSHS assesses a broad 
range of hallucinations in 
different modalities, in-
cluding auditory, visual 
and olfactory, and items 
on hypnagogic and hypno-
pompic hallucinations and 







42-item measure—designed to assess lifetime 
psychotic-like experiences in the general  
population.  
It contains 3 subscales assessing positive,  
negative psychotic  
symptoms, and depressive  
symptoms and also includes ratings  
of distress.
Good validity and reliability, especially 
in younger samples. However, positive 
and negative subscales may be less  
reliable in older adults.52
Provides comprehensive 
information about lifetime 
psychotic experiences.  








32-item measure—designed to  
assess anomalous perceptual  
experiences in the general  
community and clinical groups.  
Items scored YES or NO.  
If  YES, items then rated for distress,  
intrusiveness, and frequency on a 5-point  
Likert scale.
Good validity in nonclinical (18–54 yrs) 
and clinical (psychotic disorder) groups 
(25–64 yrs). Good internal reliability 
(Cronbach α = .87) and test-retest re-
liability over 6 months (CAPS Total 
r = .77). Total scores uncorrelated with 
age.53  
Psychometric properties in older adults 
(50 yrs and above) currently being 
examined. 
Uses neutral, everyday lan-
guage.  
Designed to assess anom-
alous perceptual experi-
ences, rather than general 
aspects of psychosis-like 
experiences.  










20-item measure—designed to  
assess hallucinations and other  
psychotic symptoms, attention, and sleep 
disturbance in Parkinson’s Disease (PD).  
Frequency is rated on a 5-point  
Likert scale: Never, < 1 time per week, 
Weekly, Most days a week, Daily.  
Distress is rated on a 4‐point Likert scale: 
None, Mild, Moderate, and Severe. 
Good validity, good test-retest  
(intra-class correlation = 0.9), and  
internal reliability (Cronbach α = 0.9) 
in older patients with idiopathic PD.56 
(Note: average age of patients with  
positive response on PsycHQ 70.5 ± 8.5 
yrs).  
Scores on Section I (core hallucinatory 
and psychotic symptoms) uncorrelated 
with age, disease duration, motor  
severity, or daily Levodopa equivalent 
dose.
Brief, typically < 10 mins.  
Developed in consultation 
with patients, caregivers, 
and clinicians and uses 
layman language.  
Questionnaire available 
from the authors upon re-
quest.  
Probes a broad spectrum 
of visual and nonvisual 
hallucinatory phenomena.  
Can help pick up PD 
hallucinations that may 
otherwise go missed by 
clinicians. Utility for as-









15-item version of the CAPE-42 measures 
positive “psychotic-like” experiences that 
have occurred in the last 3 months.  
Contains 3 subscales measuring  
persecutory ideation, bizarre  
experiences, and perceptual  
abnormalities, including ratings of distress.
Good validity and internal reliability in 
younger adults (Cronbach’s α = .79)58  




about recent hallucinatory 
and psychotic-like experi-
ences.  
Shortened version of the 
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Measure Brief  Description







43-items assess unusual sensory  
experiences in 6 modalities:  
auditory, visual, olfactory,  
gustatory, bodily sensations, and sensed  
presence.  
Items rated on a 5-point Likert scale: 0 = 
Never, 1 = Hardly Ever, 2 = Rarely,  
3 = Occasionally, and 4 = Frequently.
Acceptable test-retest reliability 
(r = .56– 0.77) and good internal  
reliability (Cronbach α = .77–88), and 
good construct and discriminant va-
lidity in nonclinical (mean = 27.75 and 
range 17–76 yrs) and clinical groups, 
including schizophrenia  
spectrum disorder and bipolar disorder 
(mean = 34.17 and range 18–67 yrs.).  




about sensory experiences 
in a number of modalities.  
Items designed to assess 
unusual sensory experi-
ences according to a  
continuum structure (ie, 
most frequent to least  
frequent phenomena).  







Structured interview for auditory hallucin-
ations (and delusions) in patients with  
psychotic disorders.  
Symptoms in the last week are rated: 
0 = no problem, 1 = minimal or occasional, 
2 = minor to moderate, 3 = major, and 
4 = maximum severity.  
Auditory hallucinations are also evaluated 
on frequency, duration, location, loudness, 
beliefs regarding origin of voices, negativity, 
distress, disruption, and controllability.
Good inter-rater and test-retest  
reliability, and good validity.  
Factor analysis shows a 4-factor  
solution measuring Distress, Frequency, 
Attribution, and Loudness.61
Provides a comprehensive, 
multidimensional  
assessment of auditory  
hallucinations.  
German, French,  
Indonesian, Malay,  






Brief  (7-items), structured clinical interview 
that measures the frequency, reality,  
loudness, number of voices, length,  
attentional salience, and distress of auditory 
hallucinations.
Adequate inter-rater and test-retest  
reliability and moderate internal  
consistency (Cronbach’s α = .60).62  
Psychometric properties in older adults 
not explored.
Provides a shorter  







Semi-structured interview designed to assess 
hallucinations in older adults with eye  
disease and cognitive impairment.  
Qualitative items rated on a 3-point Likert 
scale: 0 = never, 1 = sometimes, and  
2 = always.
Good validity and good inter-rater and 
internal reliability (Cronbach α = .71).65  
Good convergent and divergent validity 
in older adults with PD  
(mean age 68.9 ± 7.6 yrs).66
Includes brief  screening 
questions.  
Examines both simple and 
complex visual  
hallucinations.  
Explores social, emotional, 




Single-item measure (“Have you in the last 
year experienced the so-called phantom 
smells?”) scored 0 = “Never” to  
4 = “Always.” When present, fixed follow-up 
questions enquire about the type, intensity, 
duration, frequency, recency, and chronology 
of the experience.
Psychometric properties not formally 
assessed. However, phantosmia was not 
correlated with olfactory dysfunction, 
supporting the discriminant validity of 
objective and subjective olfactory  
measures.  
Prevalence of phantosmia reported to 
be uncorrelated with age in healthy  
individuals (60–90 yrs).
Brief  administration time.  
Captures qualitative  
features of phantom 
smells.  
Some people may not fully 
understand the meaning 
of Phantosmia. Responses 
may be subject to bias. 
Assessment of 
Phantosmia.68
Standardized assessment with a single,  
negatively valenced item “Do you sometimes 
smell an unpleasant, bad, or burning odor 
when nothing is there?”  
Responses coded: Yes/No.
Psychometric properties not reported.  
For adults 40 yrs and above, an  
age-related decline in unpleasant, bad, 
or burning phantosmia observed for 
women but not men.
Assessment limited to  
olfactory modality.  
Positive or neutral 
phantom smells are not 
assessed.  
No information on  
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loss. Early provision of information about the risk of 
hallucinations is emphasized as a way of reducing stigma 
and for healthcare professionals to routinely ask about 
hallucinations—to shift the onus of reporting hallucin-
ations away from the patient. The point at which specific 
pharmacological or non-pharmacological interventions 
for hallucinations are required is not clearly defined in 
guidelines but based on clinical judgment.
Differential Diagnosis
Before commencing treatment, it must be clear that hal-
lucinations are causing distress, ie, that there is a need for 
treatment. If  this is the case, the second point of attention 
is whether it is indeed hallucinations. Especially in older 
adults with cognitive dysfunction, it can be difficult to dis-
entangle hallucinations from obsessions, misperceptions/
misunderstandings (ie, illusions), or involuntary mental 
imagery, such as the so-called "earworms” (ie, songs in 
the mind that continually repeat).80
Purpose of Treatment
For some disorders, such as intoxication, psychotic de-
pression, and schizophrenia, hallucinations may respond 
well to treatment of the underlying disorder. However, 
in other disorders, such as dementia, vision or hearing 
loss, or Parkinson’s disease, this is not the case. In such 
instances, additional treatment aimed specifically at hal-
lucinations may be indicated. For the treatment of hal-
lucinations, the most important question is what the aim 
of treatment should be. There are a number of answers 
frequently given to this question:
1. I want to understand why I  experience these 
hallucinations.
2. I want to be competent to handle these hallucinations.
3. I want to get rid of these hallucinations.
For Purpose 1: Psychoeducation. If  the response to this 
question is in line with answer 1, then psychoeducation is 
the treatment of choice. In one or more sessions, the pa-
tient and his/her loved one can be provided with informa-
tion about how perception is accomplished in the brain, 
how this process can go awry, and which factors can pre-
cipitate hallucinations. A good start for psychoeducation 
is to ask the patient what he/she already knows and which 
explanation he/she currently uses for this experience. 
From there, unhelpful explanations can be corrected and 
new knowledge can be added to improve disease insight.
For Purpose 2: Psychological Therapy. If the answer is close 
to the description under point 2, then psychological therapy 
that helps the person to develop effective (and avoid inef-
fective) strategies and skills for coping with hallucinations, 
and any distress associated with these experiences, is recom-
mended. Cognitive behavioral therapies help clients think 
and feel differently about hallucinations. Improving coping 
skills can also help to reduce distress, which may contribute 
to the onset or maintenance of hallucinations.81 In the case 
of bereavement hallucinations, it is important to take a 
relational psychotherapeutic perspective on the experience, 
as the distress may signify relationship difficulties with the 
deceased, eg unfinished business and intrusive presence.82,83 
Several psychotherapies initially developed for treating 
people with a primary psychotic disorder and auditory hal-
lucinations (cognitive behavioral therapy, COMET, accept-
ance, and commitment) are also applied to older persons,84,85 
though less is known about the application of cognitive be-
havioral therapy for distressing visual hallucinations.86 In 
some cases, adjustments need to be made when the cognitive 
resources of patients are limited. The essence of such ther-
apies is that the patient learns that hallucinations are not a 
real-life threat, may have personal significance or meaning, 
or can safely be ignored. If (auditory) hallucinations have 
neutral content, then psychotherapy developed for tinnitus 
may be a better fit, as it focuses on the reduction of worry, 
and shifting attention away from the unwanted perceptions.87
For Purpose 3: The Following Steps Can Be Used. Step 
1: Check Medication Checking medication records is 
important since several types of medication can induce 
Table 4. Continued
Measure Brief  Description





50-item QPE designed to assess the presence, 
severity, and phenomenology of  
hallucinations (and delusions) across  
diagnostic groups. 
Good validity and good test-retest 
reliability, inter-rater reliability, and 
internal consistency in patients with 
schizophrenia, schizoaffective disorder, 
bipolar disorder, and major depressive 
disorder and nonclinical participants 
(mean age: 40.3, 43.4, 32.1, 30.2, and 
28.6 yrs, respectively).  
Psychometric properties in older adults/
other diagnoses currently under  
examination.
Designed for use across a 
range of disorders.  
Available from: www.
qpeinterview.com/en  
Quite long: 20-40mins  
administration time (but 
high completion rate, see 
reference 69).  
Requires training  
No specific comparisons 
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hallucinations, especially those with anticholinergic 
activity and those that increase monoaminergic func-
tion. People with cognitive dysfunction are at partic-
ular risk for such side effects. The most commonly used 
hallucination-triggering medication are corticosteroids, 
levetiracetam (an anti-epileptic drug), anti-malaria med-
ication, dopaminergic agonists (pramipexole, rotigotine, 
ropinirole,  etc.), losartan (an antihypertensive drug), and 
opioids such as tramadol. If  there is a correlation in time 
between the onset of hallucinations and start of medica-
tion use, it may be worthwhile to taper off  that medicine 
or replace it by another one and reevaluate hallucination 
severity.
Step 2: Risk Factor Management Risk factors for hal-
lucinations include physical health, environmental, psy-
chological, and social factors. Any obvious triggers to 
the hallucinations should be identified. Comorbid phys-
ical health factors increase the risk of hallucinations, 
including visual and hearing impairment and physical 
illnesses (eg, some metabolic and endocrine disorders, and 
psychiatric disorders such as depression and psychotic 
disorders). Optimize sensory modes by using glasses, per-
haps cataract operation is an option, use hearing aids. 
Good sleep hygiene is key, with darkness in nighttime and 
bright lights (preferably sunlight) at day. In terms of envi-
ronment, it is key to provide well-lit rooms, without dark 
corners. Reduce background noise as much as possible, 
especially during conversations. At the social level, good 
company is an excellent prevention for hallucinations and 
may reduce their frequency and intensity.
Step 3: Pharmacotherapy If  the patient wants to re-
duce hallucinations and previous strategies were not suc-
cessful, pharmacotherapy can be an effective means to do 
so, although side effects may be severe, especially in older 
people. It is important to discuss the unstable course of 
hallucinations and the possibility that they will disappear 
spontaneously. Considering that hallucinations can arise 
from aberrations in many neurotransmitters systems, in-
cluding the dopaminergic, serotonergic, glutamatergic, 
and cholinergic system, then specific medication may be 
effective only in specific subtypes. The phenomenology 
of the hallucinations may provide some clues to the di-
rection of which receptor system may be involved.88 For 
example, dopamine couples salience to experiences and 
increased dopamine production can lead to highly sa-
lient, often frightening hallucinations, as seen in people 
with psychotic depression, schizophrenia, delirium, and 
post-traumatic stress disorder. Antipsychotic medication 
can be effective for this specific type of hallucinations.89–91 
As dopamine receptors decrease with age, much lower 
dosages are used for older adults; hence, the adage “start 
low, go slow” to titrate until the lowest effective dose is 
achieved. Sedative antipsychotics need to be given at 
nightime to reduce the risk of falls. Electrocardiogram 
for potential QT elongation should be performed before 
and after the start of risperidone, aripiprazole, and typ-
ical antipsychotics.92As antipsychotic use has been asso-
ciated with significant mortality and morbidity risks for 
older patients, especially those with dementia, such med-
ication should be avoided if  possible and tapered off  if  
not effective or when hallucinations have been in stable 
remission when it is used.91,93
Hallucinations, especially in the visual domain, in older 
adults can also arise from the loss of cholinergic inner-
vation, especially in people with neurodegenerative dis-
orders, such as Alzheimer’s, Huntington’s, or Parkinson’s 
disease. As acetylcholine is an important neurotrans-
mitter in sustained attention, patients with loss of cho-
linergic innervation often show drowsiness, inattention, 
and forgetfulness (“what was the reason I  went to the 
kitchen?”). Cholinesterase inhibitors such as donepezil, 
rivastigmine, and galantamine can be effective in treating 
this type of hallucination.94,95 If  using rivastigmine, 
patches may be better tolerated than pills as they provide 
fewer gastrointestinal side effects.96,97 Starting dose is usu-
ally 4.6 mg/24 hours, which is increased to 9 mg/ 24 hours 
after 3–5 weeks if  generally tolerated, although side ef-
fects are also common.98
Step 4: Physical Therapy In older individuals, pharma-
cotherapy often induces side effects. Further, antipsy-
chotic medication use in the elderly has been associated 
with increased mortality.91,93 Hence, an alternative treat-
ment may be to use electrical or magnetic therapies. 
Electroconvulsive therapy (ECT) is not only the best-
known option but also the most intensive one. ECT may 
be an excellent option for older adults with psychotic de-
pression as it is rapid and highly effective for both the 
depressive and the psychotic symptoms. Cognitive side 
effects can occur but are generally not lasting and may be 
ameliorated by the use of cholinesterase inhibitors during 
the ECT course.99 For other types of hallucinations in 
older adults, ECT is seldom used. Transcranial magnetic 
stimulation and transcranial direct (or alternating) cur-
rent stimulation have been mostly applied for auditory 
verbal hallucinations,100,101 but could also be an option for 
tactile hallucinations.102,103
Summary and Directions for Future Research
Hallucinations are common in older adults. The character 
of these experiences is varied and for many, though not 
all, they can cause significant distress. Understanding the 
diverse origins, nature, and reactions to hallucinations is 
vital in helping clinicians to provide the best level of care 
(see Resources). There is currently no consensus on the 
most suitable tool(s) for assessing hallucinations in older 
individuals, with or without a co-occurring clinical dis-
order. A range of valid and reliable measures is available 
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these were largely not designed specifically for older age 
groups. Variation in the scope and content of these meas-
ures means that: (1) the phenomenological features, emo-
tional reactions, and impact on the life of hallucinations 
in older patients may be incompletely captured and (2) 
differences in the experience of hallucinations across age 
groups or diagnostic categories may be missed. Clinicians 
also need to maintain awareness of potential barriers to 
disclosure of hallucinations and the value of gaining in-
formation from multiple sources (self, informant, and 
clinician) when discussing these experiences with older 
clients. Similarly, although treatment and management 
approaches are slowly being tailored to the needs, views, 
and context of older age groups, considerably more effort 
is needed in studying how to provide a personalized re-
sponse to older clients with hallucinations and those who 
care for them.88 Finally, future research would benefit from 
a more detailed investigation of the profile of similarities 
and differences in hallucinations across clinical disorders 
and age groups to facilitate differential diagnosis, and the 
detection of early features (“red flags”) warranting a re-
ferral to more specialized services.
Resources
• British Tinnitus Association https://www.tinnitus.org.
uk/—Provides links to professional events, decision 
tools, and resources for healthcare professionals
• BMJ Parkinson’s Disease: Summary of updated NICE 
guidelines https://www.bmj.com/content/358/bmj.j1951
• Charles Bonnet Syndrome Foundation http://www.
charlesbonnetsyndrome.org/—Provides links to re-
sources, research articles, and professionals’ toolkit.
• Esme’s umbrella http://www.charlesbonnetsyndrome.
uk/—ducation and information resource for Charles 
Bonnet syndrome.
• Perth Voices Clinic https://perthvoicesclinic.com.au/
resources-for-clinicians/—Resources for clinicians 
working with people with all forms of hallucinations
• RNIB sight loss advice https://www.rnib.org.uk/
eye-health/eye-conditions/charles-bonnet-syndrome-
cbs—Education and information resource for Charles 
Bonnet syndrome.
• Royal College of Psychiatrists / MindEd for fam-
ilies https://mindedforfamilies.org.uk/Content/other_
people_tell_me_i_am_seeing_things—Education and 
information resource older adults experiencing visual 
hallucinations.
• Tinnitus Australia https://tinnitusaustralia.org.au—
Provides information, guidance, and updates to help 
people manage their tinnitus.
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